Acute promyelocytic leukemic involvement of the optic nerves following mitoxantrone treatment for multiple sclerosis

Melissa W. Ko*, Madhura A. Tamhankar, Nicholas J. Volpe, David Porter, Cindy McGrath, Steven L. Galetta

*Corresponding author for this work

Research output: Contribution to journalArticle

4 Scopus citations


Mitoxantrone, the first immunosuppressant to receive FDA approval for treatment of worsening relapsing-remitting, secondary progressive, and progressive-relapsing multiple sclerosis (MS) is a DNA topoisomerase II inhibitor that has been associated with the development of acute promyelocytic myelogenous leukemia (APML). Central nervous system APML is a rare site of extramedullary involvement following mitoxantrone therapy. We report a patient with history of multiple sclerosis who developed bilateral optic nerve involvement as the primary manifestation of APML relapse following mitoxantrone treatment.

Original languageEnglish (US)
Pages (from-to)144-147
Number of pages4
JournalJournal of the Neurological Sciences
Issue number1-2
StatePublished - Oct 15 2008



  • Acute promyelocytic leukemia
  • Mitoxantrone
  • Multiple sclerosis
  • Optic nerve

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this